Company intelligence / Profile preview
Zhejiang DTRM Biopharma
Hangzhou, Zhejiang, China
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Zhejiang DTRM Biopharma develops innovative small molecule therapies for cancer and immune diseases. Its lead assets include BTK inhibitors and combination regimens targeting hematologic malignancies such as B-cell lymphomas and chronic lymphocytic leukemia. The company has conducted multicenter clinical trials at major academic institutions in the US and China. Notably, its triple oral therapy (DTRM-555) reached phase 2 but was terminated for certain indications; other programs remain active in early-stage trials.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesmolecular glues
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Clinical collaborations with University of PennsylvaniaYale UniversityDuke UniversityMayo Clinic Minnesota/Florida/ArizonaPeking University Cancer Hospital
Beyond the preview
Go deeper on Zhejiang DTRM Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang DTRM Biopharma.